Artiva reports Q2 net loss $21.3M; cash runway into Q2 2027; autoimmune trial progress

Artiva Biotherapeutics, Inc.

2025-Q2 EPS reported -$1.71

Net loss of $21.3M for Q2 2025 vs $17.8M in Q2 2024; R&D expenses $17.9M (up from $12.3M).
Cash, cash equivalents, and investments $142.4M as of June 30, 2025; funding into Q2 2027.
First patient treated in global Phase 2a basket trial of AlloNK + rituximab in refractory RA, Sjögren's, myositis, and scleroderma.
Over a dozen patients treated across autoimmune trials; initial safety/translational data by year-end 2025.
Lead indication for AlloNK to be disclosed by year-end 2025; initial clinical response data in 1H2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.